Figure 3
Intratumoral injection with Ad5IL-12 vector and 1 week treatment with RU486 synergistically attenuates growth of TRAMP-C1 tumors. (A) TRAMP-C1 tumors established in C57BL/6 mice were treated at week 3 following tumor cell inoculation by IT injection with 50 μl of PBS containing 5 × 108 pfu of Ad5IL-12 (filled squares) or control DL70-3 vector (empty squares) or PBS alone (empty circles). Data points are expressed as the mean ± SE. n = 8 for each data point. * indicates statistical significance of P < 0.01 for Ad5IL-12 compared to controls. (B) C57BL/6 mice treated with an intratumor injection of Ad5IL-12 (black squares), or given an additional daily IP injection with RU486 (black triangles) for 1 week were compared. * indicates statistical significance of P < 0.05 for Ad5IL-12 + RU486 compared to Ad5IL-12 alone. The ratio of cures per number of treated animals is indicated. Tumor volumes measured at 8 weeks were 4204 ± 604 mm3 for PBS, 3661 ± 1049 mm3 for DL70-3, 3194 ± 733 for RU486, 386 ± 77 mm3 for Ad5IL-12 and 133 ± 53 mm3 for Ad5IL-12 + RU486 treatment groups.